
  
    
      
        Introduction_NNP
        There_EX are_VBP approximately_RB 400000_CD cases_NNS of_IN sepsis_NN reported_VBD
        each_DT year_NN in_IN the_DT USA_NNP ,_, leading_VBG to_TO about_IN 100000_CD deaths_NNS
        annually_RB [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN ._. Indeed_RB ,_, mortality_NN from_IN sepsis_NN in_IN most_JJS
        series_NN is_VBZ reported_VBN to_TO be_VB between_IN 25_CD and_CC 40_CD %_NN ,_, with_IN
        Gram-negative_NNP bacteria_NNS being_VBG the_DT most_RBS commonly_RB encountered_VBD
        pathogens_NNS [_NN 3_CD ,_, 4_CD ,_, 5_CD ]_NN ._. The_DT severity_NN of_IN sepsis_NN may_MD
        distinguish_VB those_DT who_WP may_MD benefit_VB from_IN therapeutic_JJ blockade_NN
        of_IN their_PRP$ excessive_JJ and_CC maladaptive_JJ immune_JJ response_NN ,_, from_IN
        those_DT who_WP may_MD not_RB ._. Consequently_RB ,_, a_DT practical_JJ way_NN to_TO
        determine_VB the_DT presence_NN and_CC severity_NN of_IN sepsis_NN is_VBZ essential_JJ ._.
        Although_IN systems_NNS of_IN evaluation_NN based_VBN on_IN clinical_JJ
        observations_NNS and_CC physiologic_JJ parameters_NNS are_VBP helpful_JJ ,_, they_PRP
        have_VBP been_VBN of_IN limited_JJ use_NN for_IN predicting_VBG morbidity_NN and_CC
        mortality_NN in_IN individuals_NNS with_IN inflammatory_JJ conditions_NNS ,_,
        especially_RB in_IN surgical_JJ populations_NNS [_NN 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ,_, 10_CD ]_NN ._. An_DT
        early_JJ indicator_NN of_IN tissue_NN injury_NN should_MD improve_VB the_DT
        predictive_JJ capability_NN of_IN these_DT systems_NNS ._. Although_IN several_JJ
        cytokines_NNS have_VBP been_VBN proposed_VBN as_IN markers_NNS of_IN disease_NN
        severity_NN ,_, they_PRP are_VBP often_RB transiently_RB elevated_VBD ,_, or_CC detected_VBD
        only_RB in_IN local_JJ pools_NNS [_NN 7_CD ]_NN ._. In_IN this_DT regard_NN ,_, recent_JJ studies_NNS in_IN
        humans_NNS have_VBP revealed_VBN that_IN the_DT prohormone_NN of_IN calcitonin_NN
        (_( CT_NNP )_) ,_, procalcitonin_NN (_( ProCT_NNP )_) ,_, as_RB well_RB as_IN its_PRP$ component_NN
        peptides_NNS offer_VBP promise_NN of_IN being_VBG early_JJ and_CC useful_JJ predictive_JJ
        markers_NNS of_IN systemic_JJ inflammation_NN [_NN 11_CD ,_, 12_CD ,_, 13_CD ]_NN ._.
        CT_NNP is_VBZ a_DT neuroendocrine_NN (_( NE_NNP )_) peptide_NN that_WDT was_VBD once_RB
        thought_VBN to_TO be_VB exclusively_RB a_DT hormone_NN of_IN thyroid_NN origin_NN ._. Its_PRP$
        principal_JJ function_NN appears_VBZ to_TO be_VB the_DT conservation_NN of_IN body_NN
        calcium_NN stores_NNS in_IN certain_JJ physiologic_JJ states_NNS such_JJ as_IN
        growth_NN ,_, pregnancy_NN and_CC lactation_NN ,_, and_CC the_DT maintenance_NN of_IN
        bone_NN mineral_NN in_IN emergency_NN situations_NNS by_IN means_NNS of_IN
        attenuation_NN of_IN the_DT activity_NN of_IN osteoclasts_NNS [_NN 14_CD ]_NN ._. Further_RB
        study_NN has_VBZ revealed_VBN that_IN CT_NNP is_VBZ produced_VBN extrathyroidally_RB by_IN
        NE_NNP cells_NNS throughout_IN the_DT body_NN ,_, and_CC may_MD have_VB multiple_JJ
        functions_NNS [_NN 15_CD ,_, 16_CD ]_NN ._.
        CT_NNP is_VBZ initially_RB biosynthesized_JJ as_IN a_DT larger_JJR ProCT_NNP
        polypeptide_NN which_WDT is_VBZ subsequently_RB cleaved_JJ enzymatically_RB
        into_IN its_PRP$ components_NNS ,_, including_VBG the_DT mature_VBP ,_, active_JJ hormone_NN
        (_( Fig_NNP 1_LS )_) ._. Interestingly_RB ,_, in_IN humans_NNS with_IN severe_JJ systemic_JJ
        inflammation_NN ,_, very_RB high_JJ serum_NN levels_NNS of_IN ProCT_NNP and_CC its_PRP$
        component_NN peptides_NNS are_VBP accompanied_VBN by_IN normal_JJ or_CC only_RB
        slightly_RB increased_VBN levels_NNS of_IN mature_VBP CT_NNP [_NN 17_CD ]_NN ._. In_IN order_NN to_TO
        investigate_VB whether_IN serum_NN ProCT_NNP levels_NNS might_MD correlate_VBP with_IN
        the_DT severity_NN of_IN illness_NN in_IN sepsis_NN ,_, and_CC thus_RB might_MD provide_VB a_DT
        convenient_JJ marker_NN ,_, we_PRP employed_VBN a_DT rodent_NN model_NN of_IN
        quantifiable_JJ 
        Escherichia_NNP coli_NNS peritonitis_NNS ,_,
        modified_VBN for_IN use_NN in_IN the_DT hamster_NN [_NN 18_CD ]_NN ._. This_DT model_NN was_VBD then_RB
        utilized_JJ to_TO determine_VB the_DT metabolic_JJ perturbations_NNS
        associated_VBN with_IN the_DT procalcitonin_NN peptide_NN levels_NNS observed_VBD
        with_IN sepsis_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Animals_NNS
          Male_NNP Golden-_NNP Syrian_JJ hamsters_NNS weighing_VBG 80_CD -_: 140_CD g_SYM (_( Harlan_NNP
          Animals_NNPS ,_, Indianapolis_NNP ,_, Indiana_NNP ,_, USA_NNP )_) were_VBD housed_VBN in_IN a_DT
          controlled_VBN environment_NN and_CC were_VBD exposed_VBN to_TO 12_CD h_NN
          light-dark_JJ cycles_NNS ._. The_DT animals_NNS had_VBD unrestricted_JJ access_NN to_TO
          water_VB and_CC standard_JJ rodent_NN chow_NN throughout_IN the_DT
          experiments_NNS ._. This_DT study_NN was_VBD approved_VBN by_IN the_DT Institutional_NNP
          Animal_NNP Care_NNP and_CC Use_NNP Committee_NNP at_IN the_DT Veterans_NNP Affairs_NNPS
          Medical_NNP Center_NNP ,_, Washington_NNP ,_, DC_NNP ._.
        
        
          Bacteria_NNP
          
          Escherichia_NNP coli_NNS (_( O_NNP 18_CD :_: K_NNP 1_CD :_: H_NNP 7_CD )_) were_VBD
          obtained_VBN from_IN Dr_NNP Alan_NNP S_NNP Cross_NNP ,_, Division_NNP of_IN Communicable_NNP
          Diseases_NNP and_CC Immunology_NNP ,_, Walter_NNP Reed_NNP Army_NNP Institute_NNP of_IN
          Research_NNP ,_, Washington_NNP ,_, DC_NNP ,_, USA_NNP ._. The_DT bacteria_NNS were_VBD grown_VBN in_IN
          100_CD ml_NN of_IN LB_NNP Broth_NNP (_( Fisher_NNP Scientific_NNP ,_, Pittsburgh_NNP ,_,
          Pennsylvania_NNP ,_, USA_NNP )_) at_IN 37_CD °_NN C_NNP in_IN a_DT shaker_NN water_NN bath_NN to_TO log_VB
          phase_NN and_CC stored_VBD in_IN 250_CD μ_NN l_NN aliquots_NNS at_IN -_: 70_CD °_NN C_NNP until_IN
          use_NN ._.
          On_IN the_DT day_NN of_IN an_DT experiment_NN ,_, a_DT 250_CD μ_NN l_NN aliquot_NN of_IN
          bacteria_NNS was_VBD thawed_JJ and_CC grown_VBN in_IN 100_CD ml_NN LB_NNP broth_NN at_IN 37_CD °_NN C_NNP
          in_IN a_DT shaker_NN water_NN bath_NN to_TO log_VB phase_NN ._. The_DT optical_JJ density_NN
          of_IN the_DT specimen_NN was_VBD measured_VBN at_IN 600_CD nm_NN on_IN a_DT Stasar_NNP III_NNP
          spectrophotometer_NN (_( Gilford_NNP Instruments_NNP ,_, Oberlin_NNP ,_, Ohio_NNP ,_,
          USA_NNP )_) and_CC quantified_VBN by_IN interpolation_NN on_IN a_DT previously_RB
          constructed_VBN curve_NN of_IN optical_JJ density_NN plotted_VBD against_IN
          colony_NN forming_VBG units_NNS (_( cfu_NN )_) ._. Additional_JJ specimens_NNS were_VBD
          taken_VBN from_IN the_DT stock_NN solution_NN ,_, and_CC diluted_VBD and_CC plated_JJ to_TO
          confirm_VB the_DT counts_NNS estimated_VBN by_IN spectrophotometry_NN ._.
        
        
          Intra-abdominal_NNP pellets_NNS
          Bacterial_NNP suspensions_NNS of_IN 2_CD ._. 0_CD ×_NN 10_CD 8_CD ,_, 1_CD ._. 0_CD ×_NN 10_CD 9_CD ,_, 2_CD ._. 0_CD ×_NN
          10_CD 9_CD ,_, or_CC 4_CD ._. 0_CD ×_NN 10_CD 9_CD cfu_NN /_NN ml_NN 
          E_NNP coli_NNS were_VBD pipetted_JJ in_IN 0_CD ._. 5_CD ml_NN
          aliquots_NNS into_IN 8_CD mm_NN plastic_NN embedding_VBG molds_NNS
          (_( Shandon-_NNP Upshaw_NNP ,_, War-rington_NNP ,_, Pennsylvania_NNP ,_, USA_NNP )_) ._. Each_DT
          pellet_NN for_IN implantation_NN was_VBD made_VBN by_IN adding_VBG 0_CD ._. 5_CD ml_NN sterile_JJ
          molten_NN agar_NN at_IN 50_CD °_NN C_NNP to_TO the_DT bacterial_JJ suspension_NN ,_, after_IN
          which_WDT the_DT mixture_NN was_VBD allowed_VBN to_TO solidify_VB at_IN room_NN
          temperature_NN ._. The_DT final_JJ number_NN of_IN viable_JJ colony_NN forming_VBG
          units_NNS of_IN bacteria_NNS in_IN each_DT pellet_NN was_VBD 1_CD ._. 0_CD ×_NN 10_CD 8_CD ,_, 5_CD ._. 0_CD ×_NN 10_CD
          8_CD ,_, 1_CD ._. 0_CD ×_NN 10_CD 9_CD ,_, or_CC 2_CD ._. 0_CD ×_NN 10_CD 9_CD cfu_NN /_NN pellet_NN ._.
        
        
          Experimental_NNP protocol_NN
          
            Mortality_NNP studies_NNS
            Individual_JJ hamsters_NNS were_VBD assigned_VBN to_TO four_CD groups_NNS (_( 
            n_NN =_SYM 16_CD /_NN group_NN )_) to_TO receive_VB
            progressively_RB increasing_VBG inocula_NN of_IN bacteria_NNS ._. After_IN
            adequate_JJ anesthesia_NN with_IN 50_CD mg_NN /_NN kg_NN pentobarbital_NN via_IN
            intraperitoneal_NN injection_NN ,_, the_DT abdomen_NN of_IN each_DT animal_NN
            was_VBD prepared_VBN with_IN 70_CD %_NN alcohol_NN and_CC incised_JJ in_IN the_DT
            midline_NN ._. Bacterial_NNP sepsis_NN was_VBD induced_VBN by_IN implanting_VBG one_CD
            pellet_NN in_IN the_DT right_NN lower_JJR quadrant_NN of_IN the_DT peritoneal_JJ
            cavity_NN of_IN each_DT animal_NN ._. The_DT abdominal_NN incisions_NNS were_VBD
            then_RB closed_VBN with_IN non-absorbable_JJ suture_NN ._. Animals_NNS were_VBD
            caged_JJ individually_RB ,_, given_VBN unrestricted_JJ access_NN to_TO water_VB
            and_CC rodent_NN chow_NN and_CC monitored_VBN for_IN mortality_NN over_IN a_DT 72_CD h_NN
            period_NN ._.
          
          
            Total_JJ iCT_NN studies_NNS
            After_IN intraperitoneal_NN implantation_NN of_IN agar_NN pellets_NNS
            with_IN progressively_RB increasing_VBG doses_NNS of_IN 
            E_NNP coli_NNS ,_, separate_JJ groups_NNS (_( 
            n_NN =_SYM 10_CD /_NN group_NN )_) were_VBD killed_VBN for_IN
            serum_NN total_JJ immunoreactive_JJ (_( i_NNP )_) CT_NNP determinations_NNS ._. Since_IN
            mortality_NN was_VBD evident_JJ but_CC not_RB prohibitively_RB high_JJ at_IN 12_CD
            h_NN ,_, we_PRP chose_VBD this_DT timepoint_NN to_TO determine_VB serum_NN total_JJ iCT_NN
            levels_NNS ._. Therefore_RB ,_, 12_CD h_NN after_IN animals_NNS were_VBD challenged_VBN
            with_IN 
            E_NNP coli_NNS ,_, they_PRP were_VBD anesthetized_JJ
            with_IN intraperitoneal_NN pentobarbital_NN (_( 50_CD mg_NN /_NN kg_NN )_) and_CC
            exsanguinated_JJ by_IN open_JJ cardiac_JJ puncture_NN ._. The_DT blood_NN was_VBD
            collected_VBN in_IN individual_JJ tubes_NNS and_CC centrifuged_JJ at_IN 3000_CD
            rpm_NN for_IN 15_CD min_NN ._. The_DT serum_NN specimens_NNS were_VBD transferred_VBN to_TO
            individual_JJ glass_NN tubes_NNS ,_, sealed_VBN with_IN parafilm_NN and_CC stored_VBD
            at_IN -_: 70_CD °_NN C_NNP until_IN radioimmunoassay_NN ._.
            Serum_NNP was_VBD also_RB obtained_VBN from_IN a_DT patient_NN with_IN
            documented_VBN Gram-negative_NNP sepsis_NN and_CC was_VBD stored_VBN at_IN -_: 70_CD °_NN C_NNP
            to_TO be_VB assayed_JJ with_IN the_DT hamster_NN serum_NN samples_NNS following_VBG
            G-_NNP 75_CD Sephadex_NNP gel_NN filtration_NN for_IN the_DT purpose_NN of_IN
            comparison_NN of_IN molecular_JJ forms_NNS as_IN described_VBN below_IN ._.
          
          
            Metabolic_NNP studies_NNS
            Male_NN hamsters_NNS (_( 
            n_NN =_SYM 16_CD /_NN group_NN )_) underwent_VBD
            intraperitoneal_NN implantation_NN of_IN agar_NN pellets_NNS
            impregnated_JJ with_IN 2_CD ×_NN 10_CD 9_CD cfu_NN 
            E_NNP coli_NNS (_( O_NNP 18_CD :_: K_NNP 1_CD :_: H_NNP 7_CD )_) ,_, according_VBG
            to_TO the_DT above_JJ implantation_NN protocol_NN ._. This_DT high_JJ dose_NN was_VBD
            chosen_VBN for_IN its_PRP$ ability_NN to_TO induce_VB a_DT significant_JJ increase_NN
            of_IN ProCT_NNP at_IN 12_CD h_NN in_IN the_DT proceeding_VBG experiments_NNS ._. Animals_NNS
            were_VBD killed_VBN in_IN the_DT previously_RB described_VBN fashion_NN at_IN 3_CD ,_,
            6_CD ,_, 12_CD or_CC 24_CD h_NN after_IN septic_JJ challenge_NN ._. Their_PRP$ sera_NN were_VBD
            analyzed_VBN for_IN serum_NN total_JJ iCT_NN per_IN the_DT radioimmunoassay_NN
            described_VBD below_IN ,_, as_RB well_RB as_IN for_IN total_JJ serum_NN total_JJ
            calcium_NN and_CC serum_NN albumin_NN using_VBG a_DT standard_JJ serum_NN
            multichannel_NN analyzer_NN ._.
          
          
            Radioimmunoassay_NNP
            The_DT samples_NNS were_VBD allowed_VBN to_TO warm_VB to_TO room_NN temperature_NN
            and_CC were_VBD pipetted_JJ into_IN labeled_VBN glass_NN test_NN tubes_NNS in_IN 1_CD ._. 0_CD
            ml_NN aliquots_NNS ,_, to_TO which_WDT 100_CD μ_NN l_NN dextran_NN blue_JJ (_( B-_NNP 2000_CD ,_, 2_CD
            000_CD 000_CD Da_NNP ;_: Sigma_NNP Chemical_NNP Co_NNP ,_, St_NNP Louis_NNP ,_, Missouri_NNP ,_, USA_NNP )_)
            was_VBD added_VBN ._. Five_CD milliliter_NN glass_NN columns_NNS were_VBD rinsed_JJ
            with_IN 1_CD M_NNP ammonium_NN hydroxide_NN :_: acetonitrile_NN (_( 1_CD :_: 1_LS )_) and_CC
            deionized_JJ water_NN ,_, after_IN which_WDT fine-grade_JJ polyacrylamide_NN
            gel_NN columns_NNS (_( 5_CD ml_NN )_) were_VBD prepared_VBN (_( BioGel_NNP P-_NNP 2_CD ;_: 100_CD -_: 200_CD
            mesh_VB ;_: Bio-_NNP Rad_NNP Laboratories_NNPS ,_, St_NNP Louis_NNP ,_, Missouri_NNP ,_, USA_NNP )_)
            using_VBG a_DT glass_NN bead_NN to_TO support_VB the_DT gel_NN ._. The_DT samples_NNS were_VBD
            applied_VBN to_TO the_DT columns_NNS and_CC eluted_JJ with_IN 0_CD ._. 1_CD M_NNP ammonium_NN
            bicarbonate_NN containing_VBG 0_CD ._. 1_CD %_NN Triton_NNP X-_NNP 100_CD (_( Pierce_NNP ,_,
            Rockford_NNP ,_, Illinois_NNP ,_, USA_NNP )_) ._. The_DT specimens_NNS containing_VBG
            dextran_NN blue_NN were_VBD then_RB recovered_VBN in_IN their_PRP$ original_JJ test_NN
            tubes_NNS ,_, to_TO which_WDT ethyl_NN alcohol_NN was_VBD added_VBN in_IN a_DT 2_CD :_: 1_CD volume_NN
            ratio_NN ._. These_DT mixtures_NNS were_VBD then_RB centrifuged_JJ at_IN 3000_CD rpm_NN
            for_IN 30_CD min_NN ,_, after_IN which_WDT the_DT supernatant_NN for_IN each_DT was_VBD
            decanted_JJ into_IN new_JJ tubes_NNS and_CC the_DT pellet_NN discarded_VBN ._. The_DT
            solvent_JJ was_VBD removed_VBN using_VBG a_DT Savant_NNP SpeedVac_NNP Plus_NNP
            (_( SC_NNP 110_CD A_DT )_) over_IN 2_CD -_: 4_CD h_NN ._. The_DT residue_NN for_IN each_DT sample_NN was_VBD
            then_RB reconstituted_JJ to_TO the_DT original_JJ specimen_NN volume_NN
            using_VBG gelatin_NN buffer_NN (_( 0_CD ._. 2_LS %_NN gelatin_NN in_IN borate_NN buffer_NN
            with_IN 0_CD ._. 01_CD %_NN merthiolate_NN and_CC 0_CD ._. 1_CD %_NN Triton_NNP X-_NNP 100_CD )_) ._. Using_VBG
            these_DT techniques_NNS ,_, peptide_NN recovery_NN is_VBZ approximately_RB
            80_CD %_NN ._.
            The_DT radioimmunoassay_NN design_NN was_VBD similar_JJ to_TO that_DT
            previously_RB reported_VBD [_NN 19_CD ]_NN ._. Initially_RB ,_, hamster_NN serum_NN
            total_JJ iCT_NN from_IN gel_NN filtration_NN studies_NNS was_VBD determined_VBN by_IN
            using_VBG an_DT antiserum_NN to_TO the_DT carboxyl-terminal_JJ portion_NN of_IN
            mature_VBP human_JJ CT_NNP ,_, Ab_NNP 4_CD ._. This_DT antiserum_NN reacts_VBZ with_IN the_DT CT_NNP
            molecule_NN ,_, whether_IN it_PRP is_VBZ in_IN the_DT free_JJ ,_, amidated_JJ ,_, 32_CD -_: amino_JJ
            acid_NN mature_VBP form_NN ,_, or_CC within_IN its_PRP$ precursor_NN propeptides_NNS
            [_NN ie_NN procalcitonin_NN ,_, the_DT conjoined_JJ calcitonin_NN :_: calcitonin_NN
            carboxypeptide-_NN I_PRP (_( CT_NNP :_: CCP-_NNP 1_LS )_) ,_, or_CC the_DT free_JJ immature_NN ,_,
            unamidated_JJ CT_NNP ]_NN ._. Subsequent_JJ studies_NNS were_VBD performed_VBN with_IN
            a_DT new_JJ antibody_NN ,_, R_NN 1_CD B_NNP 4_CD ,_, which_WDT has_VBZ ten_CD times_NNS the_DT
            crossreactivity_NN of_IN Ab-_NNP 4_CD with_IN the_DT prohormone_NN ._. The_DT buffer_NN
            was_VBD 0_CD ._. 2_CD %_NN gelatin_NN (_( 0_CD ._. 13_CD M_NNP H_NNP 
            3_CD BO_NNP 
            3_CD containing_VBG 9_CD g_SYM NaCl_NNP ,_, 2_CD g_SYM gelatin_NN ,_,
            1_CD ml_NN Triton-_NNP X_NNP 100_CD and_CC 0_CD ._. 1_CD g_SYM merthiolate_NN /_NN l_NN at_IN pH_NN =_SYM 7_CD ._. 5_LS )_) ._.
            The_DT antiserum_NN was_VBD preincubated_JJ with_IN standards_NNS or_CC
            unknowns_NNS (_( 20_CD -_: 100_CD μ_NN l_NN )_) in_IN 0_CD ._. 2_CD ml_NN at_IN 4_CD °_NN C_NNP for_IN 4_CD days_NNS ._.
            After_IN addition_NN of_IN 50_CD μ_NN l_NN 125_CD I-_NNP hCT_NN ,_, and_CC 200_CD μ_NN l_NN gelatin_NN
            buffer_NN ,_, incubation_NN was_VBD continued_VBN for_IN 2_CD days_NNS ._. After_IN
            adding_VBG 50_CD μ_NN l_NN goat_NN anti-rabbit_JJ IgG_NNP bound_VBN to_TO iron_VB
            particles_NNS ,_, incubation_NN was_VBD continued_VBN in_IN 0_CD ._. 5_CD ml_NN for_IN 1_CD
            day_NN ._. Bound_NNP and_CC free_JJ hormone_NN were_VBD separated_VBN with_IN
            magnetic_JJ tube_NN racks_NNS ._. Maximum_NNP bound_VBN =_SYM 37_CD %_NN ;_: sensitivity_NN
            =_SYM 1_CD g_SYM ;_: 50_CD %_NN B_NNP /_NN Bo_NNP =_SYM 50_CD pg_NN ._.
          
          
            Gel_NNP filtration_NN
            Similarly_RB to_TO work_VB previously_RB reported_VBD [_NN 20_CD ]_NN ,_,
            constituted_VBD extracts_NNS ,_, in_IN 1_CD -_: 10_CD ml_NN 0_CD ._. 2_CD %_NN gelatin_NN or_CC 0_CD ._. 2_CD %_NN
            HSA_NNP ,_, were_VBD applied_VBN to_TO calibrated_VBN 2_CD ._. 5_CD ×_NN 100_CD cm_NN columns_NNS
            containing_VBG G-_NNP 75_CD superfine_NN Sephadex_NNP (_( Pharmacia_NNP Biotech_NNP ,_,
            Piscataway_NNP ,_, New_NNP Jersey_NNP ,_, USA_NNP )_) suspended_VBN in_IN 0_CD ._. 1_CD %_NN human_JJ
            serum_NN albumin_NN (_( 1_CD g_SYM HSA_NNP ,_, 0_CD ._. 1_CD mol_NN NH_NNP 
            4_CD HCO_NNP 
            3_CD and_CC 0_CD ._. 1_CD g_SYM merthiolate_NN /_NN l_NN at_IN pH_NN =_SYM
            7_CD ._. 5_LS )_) at_IN 4_CD °_NN C_NNP ._. One_CD hundred_CD fractions_NNS (_( 120_CD drops_NNS or_CC 5_CD ._. 5_CD
            ml_NN /_NN tube_NN )_) were_VBD collected_VBN during_IN 48_CD h_NN in_IN 16_CD ×_NN 100_CD mm_NN
            borosilicate_NN glass_NN culture_NN tubes_NNS ._. The_DT void_NN volume_NN (_( VV_NNP )_)
            was_VBD based_VBN on_IN the_DT peak_NN elution_NN volume_NN (_( EV_NNP )_) of_IN blue_JJ
            dextran_NN ,_, and_CC the_DT salt_NN volume_NN (_( SV_NNP )_) was_VBD based_VBN on_IN the_DT peak_JJ
            EV_NNP of_IN Na_NNP 125_CD I_PRP ._. The_DT Kav_NNP for_IN individual_JJ components_NNS was_VBD
            determined_VBN according_VBG to_TO the_DT formula_NN :_: Kav_NNP =_SYM
            (_( EV-VV_NNP )_) /_NN (_( SV-VV_NNP )_) ._.
          
        
      
      
        Results_NNS
        
          Mortality_NNP
          The_DT mortality_NN rates_NNS at_IN 72_CD h_NN for_IN animals_NNS receiving_VBG
          progressively_RB increasing_VBG doses_NNS of_IN bacteria_NNS (_( 
          n_NN =_SYM 16_CD /_NN group_NN )_) were_VBD 0_CD ,_, 20_CD ,_, 70_CD ,_, and_CC
          100_CD %_NN ,_, respectively_RB ._. Differences_NNS in_IN mortality_NN between_IN all_DT
          groups_NNS ,_, including_VBG control_NN animals_NNS (_( 
          n_NN =_SYM 17_CD )_) ,_, were_VBD significant_JJ by_IN
          Chi-square_NNP (_( 
          P_NN =_SYM 0_CD ._. 001_CD )_) ._. Furthermore_RB ,_, these_DT
          values_NNS represent_VBP a_DT direct_JJ relationship_NN between_IN the_DT size_NN
          of_IN the_DT inoculum_NN of_IN 
          E_NNP coli_NNS and_CC mortality_NN (_( Fig_NNP 2_LS )_) ._.
        
        
          Serum_NNP total_JJ iCT_NN levels_NNS
          Hamsters_NNP which_WDT were_VBD subjected_VBN to_TO these_DT graded_JJ doses_NNS of_IN
          sepsis_NN (_( 
          n_NN =_SYM 10_CD /_NN group_NN )_) had_VBD serum_NN total_JJ iCT_NN
          levels_NNS at_IN 12_CD h_NN (_( mean_VB ±_NN SEM_NNP )_) of_IN 250_CD ±_NN 90_CD ,_, 380_CD ±_NN 60_CD ,_, 1960_CD ±_NN
          490_CD ,_, and_CC 4020_CD ±_NN 510_CD pg_NN /_NN ml_NN ,_, respectively_RB ._. Control_NN animals_NNS
          (_( 
          n_NN =_SYM 17_CD )_) had_VBD serum_NN total_JJ iCT_NN levels_NNS
          of_IN 21_CD ±_NN 2_CD pg_NN /_NN ml_NN ._. All_DT groups_NNS were_VBD statistically_RB distinct_JJ ,_,
          except_IN between_IN 0_CD and_CC 20_CD %_NN mortality_NN (_( 
          P_NN =_SYM 0_CD ._. 001_CD ,_, Kruskal-_NNP Wallis_NNP one-way_JJ
          ANOVA_NNP ;_: Fig_NNP 3_LS )_) ._.
        
        
          Molecular_NNP species_NNS of_IN the_DT total_JJ serum_NN iCT_NN
          The_DT molecular_JJ species_NNS of_IN the_DT total_JJ serum_NN iCT_NN in_IN the_DT
          serum_NN was_VBD determined_VBN by_IN radioimmunoassay_NN of_IN fractions_NNS
          obtained_VBN from_IN Sephadex_NNP gel_NN filtration_NN of_IN pooled_VBN hamster_NN
          sera_NN as_IN described_VBN above_IN ._. The_DT molecular_JJ mass_NN of_IN the_DT
          predominant_NN species_NNS of_IN iCT_NN measured_VBN (_( ie_NN >_NN 90_CD %_NN )_) was_VBD
          approximately_RB 14_CD 000_CD Da_NNP ._. From_IN previous_JJ data_NNS [_NN 31_CD ]_NN ,_, it_PRP is_VBZ
          known_VBN that_IN this_DT fraction_NN corresponds_NNS to_TO ProCT_NNP ,_, which_WDT in_IN
          humans_NNS is_VBZ 12795_CD Da_NNP ._. As_IN shown_VBN in_IN Fig_NNP 4_CD ,_, this_DT molecular_JJ
          fraction_NN in_IN the_DT hamster_NN co-elutes_JJ with_IN the_DT ProCT_NNP fraction_NN
          in_IN the_DT serum_NN of_IN a_DT septic_JJ patient_NN [_NN 17_CD ]_NN ._.
        
        
          Metabolic_NNP studies_NNS
          Serum_NNP total_JJ iCT_NN levels_NNS among_IN groups_NNS exposed_VBN to_TO a_DT high_JJ
          dose_NN of_IN 
          E_NNP coli_NNS (_( 
          n_NN =_SYM 13_CD -_: 15_CD )_) and_CC killed_VBN at_IN 3_CD ,_, 6_CD ,_, 12_CD
          and_CC 24_CD h_NN increased_VBD from_IN a_DT baseline_NN of_IN 21_CD ±_NN 2_CD pg_NN /_NN ml_NN (_( mean_VB
          ±_NN SEM_NNP )_) to_TO 78_CD ±_NN 3_CD ,_, 542_CD ±_NN 100_CD ,_, 3570_CD ±_NN 920_CD ,_, and_CC 4240_CD ±_NN 1080_CD
          pg_NN /_NN ml_NN ,_, respectively_RB ._. The_DT changes_NNS in_IN serum_NN total_JJ iCT_NN at_IN
          all_DT time_NN points_NNS ,_, except_IN between_IN 12_CD and_CC 24_CD h_NN ,_, were_VBD
          statistically_RB significant_JJ (_( one-way_JJ ANOVA_NNP ,_, 
          P_NN =_SYM 0_CD ._. 001_CD )_) ._.
          Total_JJ serum_NN calcium_NN levels_NNS at_IN these_DT timepoints_NNS were_VBD
          11_CD ._. 6_CD ±_NN 0_CD ._. 1_CD ,_, 12_CD ._. 1_LS ±_NN 0_CD ._. 2_CD ,_, 9_CD ._. 4_CD ±_NN 0_CD ._. 2_CD ,_, and_CC 10_CD ._. 6_CD ±_NN 0_CD ._. 4_CD mg_NN /_NN dl_NN ._.
          The_DT decrease_NN at_IN 12_CD h_NN was_VBD statistically_RB significant_JJ per_IN
          MannWhitney_NNP rank_NN sum_NN test_NN (_( 
          P_NN <_NN 0_CD ._. 05_CD )_) ._. Simple_NN linear_JJ
          regression_NN reveals_VBZ an_DT inverse_NN correlation_NN between_IN total_JJ
          calcium_NN levels_NNS and_CC total_JJ iCT_NN (_( 
          r_LS =_SYM -_: 0_CD ._. 81_CD )_) ._. Serum_NNP albumin_NN levels_NNS
          varied_VBD minimally_RB at_IN 3_CD ,_, 6_CD ,_, 12_CD and_CC 24_CD h_NN from_IN a_DT baseline_NN of_IN
          3_CD ._. 3_CD ±_NN 0_CD ._. 1_CD g_SYM /_NN dl_NN ,_, and_CC therefore_RB did_VBD not_RB account_VB for_IN the_DT
          decrease_NN in_IN measured_VBN calcium_NN ._.
        
      
      
        Discussion_NNP
        The_DT characteristics_NNS of_IN the_DT inflammatory_JJ response_NN in_IN
        sepsis_NN suggest_VBP that_IN successful_JJ treatment_NN requires_VBZ a_DT
        clinically_RB useful_JJ marker_NN which_WDT can_MD indicate_VB the_DT severity_NN of_IN
        illness_NN and_CC which_WDT is_VBZ expressed_VBN early_JJ enough_RB in_IN the_DT sepsis_NN
        cascade_NN to_TO allow_VB therapeutic_JJ interventions_NNS to_TO be_VB initiated_VBN
        in_IN a_DT timely_JJ manner_NN [_NN 4_CD ]_NN ._. Additionally_RB ,_, insights_NNS into_IN the_DT
        biosynthesis_NNS ,_, regulation_NN ,_, and_CC physiologic_JJ activity_NN of_IN such_JJ
        a_DT marker_NN may_MD illuminate_VB some_DT of_IN the_DT causative_JJ factors_NNS in_IN
        the_DT pathophysiologic_JJ and_CC clinical_JJ events_NNS of_IN the_DT sepsis_NN
        syndrome_NN ._. Furthermore_RB ,_, the_DT marker_NN itself_PRP may_MD prove_VB to_TO be_VB a_DT
        therapeutic_JJ target_NN ._.
        Serum_NNP levels_NNS of_IN ProCT_NNP as_RB well_RB as_IN its_PRP$ component_NN peptides_NNS
        are_VBP massively_RB elevated_VBD in_IN burns_NNS [_NN 11_CD ]_NN ,_, heat_NN stroke_NN [_NN 21_CD ]_NN ,_,
        systemic_JJ infections_NNS [_NN 13_CD ]_NN ,_, and_CC other_JJ inflammatory_JJ states_NNS [_NN
        12_CD ,_, 22_CD ]_NN ._. Using_VBG an_DT antiserum_NN to_TO CT_NNP which_WDT recognizes_VBZ the_DT free_JJ
        mature_VBP CT_NNP ,_, the_DT immature_NN CT_NNP within_IN the_DT ProCT_NNP molecule_NN ,_, and_CC
        the_DT conjoined_JJ CT_NNP :_: CCP-_NNP 1_CD peptide_NN ,_, we_PRP have_VBP demonstrated_VBN that_IN
        levels_NNS of_IN serum_NN total_JJ iCT_NN are_VBP also_RB elevated_VBD in_IN the_DT septic_JJ
        hamster_NN ._. Then_RB ,_, utilizing_VBG gel_NN filtration_NN techniques_NNS ,_, we_PRP
        showed_VBD that_IN much_RB of_IN this_DT iCT_NN was_VBD in_IN the_DT form_NN of_IN ProCT_NNP ;_: this_DT
        is_VBZ similar_JJ to_TO the_DT human_JJ subject_NN with_IN sepsis_NN [_NN 17_CD ,_, 23_CD ]_NN ._. Our_PRP$
        findings_NNS indicate_VBP a_DT positive_JJ correlation_NN between_IN ProCT_NNP
        component_NN peptides_NNS and_CC the_DT degree_NN of_IN sepsis_NN ._. In_IN this_DT model_NN ,_,
        the_DT series_NN of_IN metabolic_JJ experiments_NNS furthermore_RB reveal_VBP that_IN
        ProCT_NNP is_VBZ temporally_RB associated_VBN with_IN and_CC inversely_RB
        correlated_JJ with_IN serum_NN total_JJ calcium_NN levels_NNS ._.
        CT_NNP is_VBZ a_DT single_JJ chain_NN ,_, 32_CD -_: amino_JJ acid_NN peptide_NN that_WDT
        originates_VBZ from_IN the_DT CALC-I_NNP gene_NN on_IN chromosome_NN 11_CD [_NN 16_CD ]_NN ._. In_IN
        humans_NNS the_DT highest_JJS concentration_NN of_IN tissue_NN iCT_NN is_VBZ in_IN the_DT
        parafollicular_NN cells_NNS of_IN the_DT thyroid_NN gland_NN ._. However_RB ,_, iCT_NN can_MD
        be_VB detected_VBN throughout_IN the_DT body_NN in_IN NE_NNP cells_NNS of_IN various_JJ
        tissues_NNS ._. Indeed_RB ,_, in_IN humans_NNS the_DT lungs_NNS contain_VBP more_RBR total_JJ iCT_NN
        than_IN does_VBZ the_DT thyroid_NN gland_NN [_NN 24_CD ]_NN ._.
        While_IN mature_VBP CT_NNP has_VBZ diverse_JJ effects_NNS on_IN various_JJ target_NN
        tissues_NNS ,_, its_PRP$ overall_JJ physiologic_JJ significance_NN in_IN normal_JJ
        individuals_NNS is_VBZ not_RB well_RB understood_VBN ._. In_IN health_NN ,_, its_PRP$
        principal_JJ role_NN is_VBZ to_TO protect_VB against_IN excessive_JJ bone_NN
        turnover_NN during_IN times_NNS of_IN increased_VBN need_NN by_IN attenuating_VBG the_DT
        activity_NN of_IN osteoclasts_NNS [_NN 25_CD ]_NN ._. CT_NNP and_CC its_PRP$ precursors_NNS ,_,
        however_RB ,_, may_MD exert_VB other_JJ effects_NNS in_IN health_NN or_CC in_IN disease_NN [_NN
        16_CD ]_NN ._.
        The_DT polypeptide_NN precursor_NN of_IN CT_NNP ,_, pre-procalcitonin_JJ ,_,
        undergoes_NNS cleavage_NN of_IN its_PRP$ leader_NN sequence_NN early_RB in_IN
        posttranslational_NN processing_NN to_TO yield_VB ProCT_NNP ,_, and_CC several_JJ
        constituent_NN peptides_NNS (_( Fig_NNP 1_LS )_) ._. In_IN normal_JJ ,_, regulated_VBN
        secretion_NN ,_, ProCT_NNP is_VBZ trafficked_JJ through_IN the_DT Golgi_NNP apparatus_NN
        and_CC then_RB packaged_VBN into_IN dense-core_JJ secretory_NN vesicles_NNS [_NN 26_CD ,_,
        27_CD ]_NN ._. Proteolytic_NNP processing_NN within_IN the_DT trans-_NN Golgi_NNP and_CC the_DT
        secretory_NN vesicles_NNS culminates_VBZ in_IN the_DT formation_NN of_IN the_DT
        active_JJ ,_, mature_VBP secretory_NN product_NN ,_, CT_NNP ,_, which_WDT is_VBZ released_VBN by_IN
        exocytosis_NNS at_IN the_DT apical_JJ surface_NN of_IN the_DT NE_NNP cell_NN ._. In_IN the_DT
        absence_NN of_IN an_DT appropriate_JJ signal_NN at_IN the_DT plasma_NN membrane_NN ,_,
        these_DT vesicles_NNS serve_VBP as_IN storage_NN repositories_NNS for_IN mature_VBP
        CT_NNP ._.
        In_IN severe_JJ systemic_JJ inflammation_NN in_IN humans_NNS ,_, however_RB ,_,
        enormous_JJ levels_NNS of_IN ProCT_NNP and_CC other_JJ component_NN peptides_NNS
        appear_VBP in_IN the_DT serum_NN ,_, while_IN mature_VBP serum_NN CT_NNP remains_VBZ normal_JJ
        or_CC only_RB minimally_RB elevated_VBD [_NN 17_CD ]_NN ._. The_DT cellular_JJ source_NN of_IN
        this_DT increase_NN in_IN serum_NN levels_NNS ,_, and_CC the_DT reasons_NNS that_IN ProCT_NNP
        and_CC its_PRP$ component_NN peptides_NNS are_VBP not_RB processed_VBN to_TO the_DT mature_VBP
        hormone_NN ,_, are_VBP unknown_JJ ._. In_IN inflammatory_JJ states_NNS ,_, ProCT_NNP and_CC its_PRP$
        related_VBN peptides_NNS appear_VBP to_TO be_VB secreted_JJ by_IN a_DT continuous_JJ
        bulk-flow_JJ constitutive_JJ pathway_NN ,_, in_IN which_WDT only_RB limited_JJ
        conversion_NN to_TO mature_VB CT_NNP occurs_VBZ [_NN 28_CD ]_NN ._. One_PRP might_MD postulate_NN
        that_IN severe_JJ inflammation_NN causes_NNS such_JJ a_DT profound_JJ
        hypersynthesis_NNS of_IN the_DT prohormone_NN that_IN the_DT NE_NNP
        endoproteolytic_JJ machinery_NN is_VBZ overwhelmed_VBN ._. This_DT may_MD result_VB
        in_IN a_DT marked_VBN shift_NN to_TO the_DT constitutive_JJ pathway_NN of_IN secretion_NN ,_,
        resulting_VBG in_IN an_DT incomplete_JJ processing_NN of_IN precursors_NNS ._. In_IN
        this_DT respect_NN ,_, a_DT shift_NN to_TO constitutive_JJ secretion_NN has_VBZ been_VBN
        reported_VBN to_TO occur_VB by_IN the_DT experimental_JJ induction_NN of_IN
        dysfunctional_NN prohormone_NN convertase_NN enzymes_NNS or_CC by_IN injury_NN to_TO
        the_DT plasma_NN membrane_NN [_NN 29_CD ]_NN ._. Perhaps_RB some_DT cytokines_NNS may_MD
        induce_VB constitutive_JJ secretion_NN by_IN such_JJ a_DT process_NN [_NN 30_CD ,_, 31_CD ]_NN ._.
        It_PRP is_VBZ also_RB possible_JJ that_IN ProCT_NNP and_CC its_PRP$ component_NN peptides_NNS
        are_VBP released_VBN by_IN non-_NN NE_NNP cells_NNS ,_, which_WDT normally_RB possess_VBP
        regulatory_JJ mechanisms_NNS limiting_VBG the_DT expression_NN of_IN ProCT_NNP
        mRNA_NN ;_: these_DT inhibitory_NN mechanisms_NNS may_MD be_VB deregulated_VBN by_IN
        unusually_RB high_JJ levels_NNS of_IN inflammatory_JJ mediators_NNS ._.
        Stimulation_NNP of_IN synthesis_NN in_IN such_JJ non-_NN NE_NNP cells_NNS would_MD result_VB
        in_IN a_DT preferential_JJ production_NN of_IN ProCT_NNP because_IN these_DT cells_NNS
        lack_VBP the_DT enzymes_NNS for_IN complete_JJ prohormonal_NN processing_NN ._.
        It_PRP is_VBZ unknown_JJ what_WP impact_NN ,_, if_IN any_DT ,_, this_DT increase_NN of_IN
        ProCT_NNP and_CC related_VBN peptides_NNS has_VBZ on_IN patients_NNS ._. Hypocalcemia_NNP is_VBZ
        a_DT common_JJ finding_NN in_IN critically_RB ill_JJ and_CC especially_RB septic_JJ
        patients_NNS ._. Indeed_RB ,_, the_DT development_NN of_IN hypocalcemia_NN in_IN the_DT
        critically_RB ill_JJ has_VBZ been_VBN shown_VBN to_TO be_VB associated_VBN with_IN a_DT poor_JJ
        prognosis_NN [_NN 32_CD ,_, 33_CD ]_NN ._. ProCT_NNP contains_VBZ within_IN its_PRP$ structure_NN
        the_DT immature_NN CT_NNP molecule_NN ;_: therefore_RB ,_, very_RB high_JJ and_CC
        sustained_VBN levels_NNS of_IN ProCT_NNP might_MD mimic_VB one_CD of_IN the_DT
        pharmaco_NN /_NN physiologic_JJ activities_NNS of_IN CT_NNP ,_, which_WDT is_VBZ the_DT
        lowering_VBG of_IN serum_NN calcium_NN levels_NNS ._. In_IN our_PRP$ experiments_NNS we_PRP
        noted_VBD that_IN total_JJ iCT_NN levels_NNS peaked_VBD at_IN 12_CD h_NN following_VBG the_DT
        septic_JJ insult_NN ._. This_DT was_VBD concurrent_JJ with_IN a_DT significant_JJ
        decrease_NN in_IN serum_NN total_JJ calcium_NN ._. Nevertheless_RB ,_, this_DT
        association_NN does_VBZ not_RB prove_VB a_DT causal_NN relationship_NN between_IN
        elevated_VBD ProCT_NNP levels_NNS and_CC hypocalcemia_NN ._. Also_RB ,_, the_DT
        relationship_NN with_IN ionized_JJ calcium_NN was_VBD not_RB determined_VBN in_IN
        this_DT study_NN ._.
        The_DT early_JJ and_CC marked_VBD hypersecretion_NN of_IN ProCT_NNP and_CC its_PRP$
        component_NN peptides_NNS in_IN inflammatory_JJ states_NNS makes_VBZ them_PRP
        promising_JJ serum_NN markers_NNS for_IN the_DT sepsis_NN syndrome_NN ._. These_DT
        peptides_NNS are_VBP released_VBN into_IN the_DT central_JJ circulation_NN and_CC may_MD
        act_VB systemically_RB ,_, as_IN opposed_VBN to_TO many_JJ of_IN the_DT known_VBN mediators_NNS
        of_IN sepsis_NN ,_, which_WDT are_VBP released_VBN locally_RB and_CC often_RB act_VB in_IN an_DT
        autocrine_NN or_CC paracrine_NN fashion_NN ._. An_DT important_JJ feature_NN of_IN
        ProCT_NNP and_CC some_DT of_IN its_PRP$ component_NN peptides_NNS are_VBP their_PRP$ long_JJ
        half-lives_JJ ,_, which_WDT contribute_VBP to_TO their_PRP$ potential_JJ usefulness_NN
        as_IN serum_NN markers_NNS ._. Indeed_RB ,_, elevated_VBD levels_NNS of_IN ProCT_NNP peptides_NNS
        have_VBP been_VBN found_VBN to_TO persist_VB at_IN least_JJS 24_CD h_NN following_VBG an_DT
        appropriate_JJ stimulus_NN ,_, in_IN contradistinction_NN to_TO other_JJ
        markers_NNS ,_, such_JJ as_IN tumor_NN necrosis_NNS fctor-α_JJ ,_, whose_WP$ levels_NNS may_MD
        be_VB only_RB transiently_RB elevated_VBD after_IN an_DT inflammatory_JJ
        challenge_NN [_NN 34_CD ,_, 35_CD ]_NN ._. Thus_RB ,_, they_PRP provide_VBP a_DT long-lasting_JJ
        target_NN to_TO evaluate_VB the_DT effects_NNS of_IN immunoneutralization_NN ._.
        Accordingly_RB ,_, we_PRP recently_RB reported_VBD that_IN ProCT_NNP markedly_RB
        contributes_VBZ to_TO mortality_NN in_IN experimental_JJ sepsis_NN ,_, and_CC that_DT
        immunoneutralization_NN of_IN this_DT molecule_NN diminishes_VBZ mortality_NN
        in_IN our_PRP$ model_NN of_IN hamster_NN sepsis_NN [_NN 36_CD ]_NN ._.
        In_IN summary_NN ,_, our_PRP$ animal_NN experiments_NNS demonstrate_VBP an_DT
        association_NN between_IN levels_NNS of_IN serum_NN ProCT_NNP and_CC its_PRP$ component_NN
        peptides_NNS with_IN the_DT degree_NN of_IN sepsis_NN ,_, reinforcing_VBG clinical_JJ
        findings_NNS that_IN these_DT peptides_NNS are_VBP useful_JJ markers_NNS for_IN this_DT
        condition_NN ,_, and_CC may_MD predict_VB mortality_NN ._. Further_RB experiments_NNS
        to_TO examine_VB the_DT cellular_JJ source_NN ,_, pathophysiology_NN and_CC
        metabolic_JJ activity_NN of_IN ProCT_NNP and_CC its_PRP$ component_NN peptides_NNS are_VBP
        warranted_VBN ._. Such_JJ studies_NNS may_MD determine_VB the_DT role_NN of_IN these_DT
        hormonal_NN peptides_NNS in_IN inflammation_NN and_CC sepsis_NN ._.
      
    
  
